36 results
8-K
EX-99.1
FGEN
FibroGen Inc
7 Aug 23
FibroGen Reports Second Quarter 2023 Financial Results
4:06pm
the leadership role, I am very optimistic about our future. Within the next year, we have three pamrevlumab read-outs and key milestones for our early-stage
8-K
EX-99.1
FGEN
FibroGen Inc
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
Exhibit 99.1
FibroGen Announces Leadership Transition
Appoints Thane Wettig as Interim Chief Executive Officer
Wettig succeeds Enrique Conterno … and brings over 30 years of global pharmaceutical leadership
SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today
8-K
FGEN
FibroGen Inc
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
since June 2020, has more than 30 years of global biopharmaceutical leadership and commercial experience. Mr. Wettig previously served as Chief
8-K
EX-99.1
x230o c0t
16 Aug 21
FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer
5:23pm
8-K
48wombjf gar2mjnzu5q
16 Aug 21
FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer
5:23pm
8-K
q70v2 erz
14 May 21
Regulation FD Disclosure
5:22pm
8-K
a5pryd 5v
1 Dec 20
Departure of Directors or Certain Officers
8:05am
8-K
egamjudr 5zgt
13 Feb 20
Departure of Directors or Certain Officers
4:05pm
8-K
EX-99.1
z6frd79vciz3cjnpmsm
13 Jan 20
Regulation FD Disclosure
9:01am
8-K
EX-99.1
0vtev88b4
6 Jan 20
Fibrogen Names Enrique Conterno As Chief Executive Officer
5:23pm